The p53 codon 72 exon 4 BstUI polymorphism and endometrial cancer in Caucasian women

Oncology

Volumn 76, Issue 3, 2009, Pages 173-183

  Zubor, Pavol ^a   Stanclova, Andrea ^a   Kajo, Karol ^a   Hatok, Jozef ^a   Klobusiakova, Dasa ^a   Visnovsky, Jozef ^a   Danko, Jan ^a  

^a University Teaching Hospital in Martin   (Slovakia)

Author keywords

Codon 72; Endometrial cancer; Histology; p53 gene; Polymorphism

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RISK; CAUCASIAN; CODON; CONTROLLED STUDY; DISEASE MARKER; DNA POLYMORPHISM; ENDOMETRIUM CANCER; EXON; FEMALE; GENE FREQUENCY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENARCHE; MENOPAUSE; PELVIS LYMPH NODE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SEQUENCE ANALYSIS; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CASE-CONTROL STUDIES; CODON; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; ENDOMETRIAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXONS; FEMALE; GENES, P53; GENOTYPE; HUMANS; MENARCHE; MENOPAUSE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 59649124239     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000201570     Document Type: Article

References (34)

1. Levi F, Lucchini F, Negri E, Zatonski W, Boyle P, La Vecchia C: Trends in cancer mortality in the European Union and accession countries, 1980-2000. Ann Oncol 2004;15:1425-1431.
2. Boyle P, Ferlay J: Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16:481-488.
3. Woods DB, Vousden KH: Regulation of p53 function. Exp Cell Res 2001;264:56-66.
4. Kang S, Roh JW, Kim JW: Single nucleotide polymorphism: a new risk factor for endometrial cancer? Future Oncol 2005;1:323-330.
5. Weber BL, Nathanson KL: Low penetrance genes associated with increased risk for breast cancer. Eur J Cancer 2000;36:1193-1199.
6. Kotnis A, Sarin R, Mulherkar R: Genotype, phenotype and cancer: role of low penetrance genes and environment in tumour susceptibility. J Biosci 2005;30:93-102.
7. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV: Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7:961-963.
8. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-365.
9. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L: Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-234.
10. Siddique M, Sabapathy K: Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 2006;25:3489-3500.
11. Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, Yamaguchi H, Nishiyama K, Yasuda M, Ueki M: Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol Oncol 2006;100:173-178.
12. Roh JW, Kim JW, Park NH, Song YS, Park IA, Park SY, Kang SB, Lee HP: p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol 2004;93:499-505.
13. Niwa Y, Hirose K, Matsuo K, Tajima K, Ikoma Y, Nakanishi T, Nawa A, Kuzuya K, Tamakoshi A, Hamajima N: Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett 2005;219:183-190.
14. Agorastos T, Masouridou S, Lambropoulos AF, Chrisafi S, Miliaras D, Pantazis K, Constantinides TC, Kotsis A, Bontis I: P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur J Cancer Prev 2004;13:277-280.
15. Peller S, Halperin R, Schneider D, Kopilova Y, Rotter V: Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol Rep 1999;6:193-197.
16. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J: Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br J Cancer 1997;75:1385-1388.
17. Saffari B, Bernstein L, Hong DC, Sullivan-Halley J, Runnebaum IB, Grill HJ, Jones LA, El-Naggar A, Press MF: Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas. Int J Gynecol Cancer 2005;15:952-963.
18. Silverberg SG, Kurman RJ, Nogales F, Mutter GL, Kubik-Huch RA, Tavassoli FA: Epithelial tumours and related lesions; in Tavassoli FA, Devilee P (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, IARC Press, 2003, pp 221-232.
19. Sjalander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L: p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 1996;17:1313-1316.
20. Sjalander A, Birgander R, Kivela A, Beckman G: p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered 1995;45:144-149.
21. Sjalander A, Birgander R, Saha N, Beckman L, Beckman G: p53 polymorphisms and haplotypes show distinct differences between major ethnic groups. Hum Hered 1996;46:41-48.
22. Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-17.
23. Lax SF: Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004;444:213-223.
24. Sherman ME, Bur ME, Kurman RJ: p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-1274.
25. Potischman N, Hoover RN, Brinton LA, Siiteri P, Dorgan JF, Swanson CA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Persky V, Lurain JR: Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996;88:1127-1135.
26. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP, Eng C: Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-930.
27. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L: p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-185.
28. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-1100.
29. Langerod A, Bukholm IR, Bregard A, Lonning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA, Børresen-Dale AL: The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 2002;11:1684-1688.
30. Tada M, Furuuchi K, Kaneda M, Matsumoto J, Takahashi M, Hirai A, Mitsumoto Y, Iggo RD, Moriuchi T: Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis 2001;22:515-517.
31. Furihata M, Takeuchi T, Matsumoto M, Kurabayashi A, Ohtsuki Y, Terao N, Kuwahara M, Shuin T: p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin Cancer Res 2002;8:1192-1195.
32. Sakamuro D, Sabbatini P, White E, Prendergast GC: The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 1997;15:887-898.
33. Campomenosi P, Monti P, Aprile A, Abbondandolo A, Frebourg T, Gold B, Crook T, Inga A, Resnick MA, Iggo R, Fronza G: p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 2001;20:3573-3579.
34. Di Como CJ, Gaiddon C, Prives C: p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 1999;19:1438-1449.